Program
bicalutamide
Also written as “Bicalutamide”, “ICI176,334-1” and “Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)”.
Its studies are mostly in Prostatic Neoplasms · Lower Urinary Tract Symptoms · Puberty, Precocious · Gynecomastia, led by 5 companies.
Drug pageBicalutamide: every studyMany companies study it; this page follows only the 21 they lead. All 94 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 130 open or running | phase 4since Oct 26, 2005 | Oct 16, 2004 | none ahead |
| Alessa Therapeutics | 21 open or running | phase 1since Feb 12, 2020 | Feb 12, 2020 | Apr 24, 2027phase 1 · NCT04943536 |
| Kremers Urban Developmentits history only | 20 open or running | phase 1since Dec 23, 2009 | Dec 23, 2009 | none ahead |
| Novartisits history only | 20 open or running | phase 1since Aug 13, 2009 | Aug 13, 2009 | none ahead |
| Teva Pharmaceutical Industriesits history only | 20 open or running | phase 1since Sep 8, 2009 | Sep 8, 2009 | none ahead |
Also a collaborator on its studies: AbbVie.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Alessa Therapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 12, 2020First study: phase 1 study in Lower Urinary Tract SymptomsFirst studyNCT04284761 · 17 enrolled · United States, Australia, New Zealand
- Jun 15, 2021Phase 1 study in Prostate AdenocarcinomaNCT04943536 · 20 enrolled · United States
Ahead
- Apr 24, 2027Primary completion: phase 1 study in Prostate AdenocarcinomaNCT04943536
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 Alessa Therapeutics leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04943536Prostate Adenocarcinoma · United States | 1 | Active, not recruiting | Apr 24, 2027 | 20 |
| NCT04284761Lower Urinary Tract Symptoms · United States, Australia, New Zealand | 1 | Completed | May 3, 2023 | 17 |
How it is read
Names in the registry
- “Bicalutamide”, 9 entries
- “ICI176,334-1”, 4 entries
- “bicalutamide”, 2 entries
- “Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)”, 2 entries
- “Casodex 80 mg tablet”, 2 entries
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 10 studies
- Lower Urinary Tract Symptoms, 1 study
- Puberty, Precocious, 1 study
- Gynecomastia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.